Ivonescimab Significantly Improves Overall Survival vs. Pembrolizumab in First-Line PD-L1 Positive Advanced NSCLC

September 20, 2026

The ASCO Post Unknown

Overview

Ivonescimab, a first-in-class PD-1/VEGF bispecific antibody, demonstrated a statistically significant and clinically meaningful improvement in overall survival (OS) compared to pembrolizumab as a first-line treatment for PD-L1 positive advanced non-small cell lung cancer (NSCLC). This groundbreaking data emerged from a pre-specified interim analysis of the Phase III HARMONi-2 trial, presented at the IASLC 2026 World Conference on Lung Cancer (WCLC). The results suggest Ivonescimab could become a superior therapeutic option, potentially altering the treatment paradigm for advanced NSCLC patients.

In Depth

Key Findings

A significant breakthrough has been announced for the treatment of PD-L1 positive advanced non-small cell lung cancer (NSCLC). Ivonescimab, a first-in-class PD-1/VEGF bispecific antibody, demonstrated a statistically significant and clinically meaningful improvement in overall survival (OS) when compared to the current standard of care, pembrolizumab, in patients receiving first-line treatment. This pivotal data was derived from a pre-specified interim analysis of the Phase III HARMONi-2 study, presented at the International Association for the Study of Lung Cancer (IASLC) 2026 World Conference on Lung Cancer (WCLC) in Seoul, South Korea.

Technical / Clinical Details

Ivonescimab is an innovative bispecific antibody designed to simultaneously target two critical pathways in cancer: the programmed death-1 (PD-1) pathway and the vascular endothelial growth factor (VEGF) pathway. By inhibiting PD-1, it aims to reactivate anti-tumor T-cell responses, similar to conventional immune checkpoint inhibitors. Concurrently, by inhibiting VEGF, it suppresses tumor angiogenesis, which starves the tumor of nutrients, and also modulates the tumor microenvironment to make it more permissive to immune cell infiltration and activity. The Phase III HARMONi-2 trial compared Ivonescimab monotherapy against pembrolizumab monotherapy in patients with PD-L1 positive advanced NSCLC. The superior OS demonstrated by Ivonescimab suggests that its dual mechanism of action may overcome some of the limitations of single-target immune checkpoint inhibitors. While specific median OS values, hazard ratios, and detailed safety profiles were not explicitly provided in the interim analysis report, the emphasis on statistical significance and clinical meaningfulness underscores the profound impact of these results.

Background & Context

NSCLC is a leading cause of cancer-related deaths globally, and for patients with advanced disease, especially those with high PD-L1 expression, immune checkpoint inhibitors (ICIs) have become a cornerstone of therapy. Pembrolizumab (Keytruda®) is one of the most prominent drugs in this class. However, a substantial number of patients either do not respond to ICIs or develop resistance over time, creating a persistent need for more effective treatment strategies. The rationale for targeting both PD-1 and VEGF with a bispecific antibody is strong, as it addresses two key drivers of cancer progression—immune evasion and angiogenesis—simultaneously. This synergistic approach is hypothesized to deliver superior clinical outcomes by creating a more potent and comprehensive anti-tumor effect, and by re-educating the tumor microenvironment for enhanced immune attack.

Strategic Significance & Outlook

The highly positive OS results for Ivonescimab from the HARMONi-2 study have the potential to fundamentally shift the treatment paradigm for PD-L1 positive advanced NSCLC. This evidence strongly supports the notion that bispecific antibodies can offer enhanced clinical benefits over existing monoclonal antibodies. Anticipation is high for the release of detailed clinical data, including median OS, PFS, objective response rates, and comprehensive safety profiles. Regulatory submissions for approval are expected to follow swiftly. Should Ivonescimab gain approval, it would provide a new, more powerful first-line treatment option for advanced NSCLC patients, leading to improved long-term outcomes and offering renewed hope to a patient population in dire need of therapeutic advancements.

Source: https://ascopost.com/news/september-2026/ivonescimab-significantly-improves-overall-survival-vs-pembrolizumab-in-pd-l1-positive-advanced-nsclc/

Get our weekly technology intelligence — free

Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.

Subscribe Free — Weekly Tech Intelligence

By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.